A 55-year-old patient with non-smallcell lung cancer suffered from productive cough due to bronchopulmonary fistula (BPF) following pneumectomy ( figure 1A,B) . First, we used vascular occlusion coils (Tornado Platin Embolization Coils, Cook, Limerick, Ireland, traditionally used for embolisation of selective vessel supply to arteriovenous malformations) placed endobronchially in conjunction with fibrin glue application ( figure 1C) . However, the occluding material was expectorated only 1 week later, probably due to the size of the fistula (10 mm). Second, an Amplatzer vascular plug IV (St. Jude Medical, St. Paul, Minnesota, USA, made of nitinol wires and used for transcatheter embolisation in the peripheral vasculature and occlusion of abnormal vessel communications) was delivered into the fistula ( figure 1D ). A few weeks later, a bronchography could assure correct device positioning and sealing of the BPF; however, a second small BPF was visualised. Third, an Angio-Seal (St. Jude Medical, St. Paul, Minnesota, USA) vascular closure device (that quickly seals femoral artery punctures following catheter procedures) was used for the new BPF. After insertion of a J wire from the pleural space and snaring it via the bronchoscope (figure 1E), the Angio-Seal was placed and the collagen plug was directed into the fistula and deployed under bronchoscopic guidance (figure 1F,G). After 2 months, the patient remained well, and the fistulae were clinically closed.
< Endobronchial closure of bronchopulmonary fistula is a safe and effective method, at least in selected patients. < Combined use of different devices may be necessary.
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CFTR potentiator for cystic fibrosis
This multicentre, double blinded, randomised controlled trial assessed the efficacy of ivacaftor, a cystic fibrosis transmembrane conductance regulator (CFTR) protein potentiator.
The primary outcome of the trial was the change in the forced expiratory volume in 1 s (FEV 1 ). The secondary outcomes were time to the first pulmonary exacerbation and subjectreported respiratory symptoms. The trial included 161 subjects who were 12 years of age or above with the G551D mutation.
The study showed a treatment effect of 10.6% in FEV 1 (p<0.001) in patients with a starting FEV 1 <70% predicted. There was a 55% reduction in the risk of pulmonary exacerbation and a statistically significant improvement in subject-reported respiratory symptoms by 48 weeks. The study showed no significantly increased rate of adverse effects or dropout rate associated with ivacaftor. The study was not powered to assess the treatment effects in different demographic subgroups.
The G551D mutation is present only in approximately 4%e5% of cystic fibrosis patients and produces a defective CFTR protein which localises onto the epithelial cell surfaces. In the commonest CFTR mutation, F508del, the CFTR protein is however unable to reach the cell surfaces. Ivacaftor, given its mechanism of action, is therefore not applicable to this larger patient group.
The study has shown potential clinical applications which have arisen through our increased understanding of the CFTR gene. The effects of ivacaftor beyond 48 weeks and in combination therapy for individuals with other CFTR mutations would be interesting areas of research and may broaden the clinical application of ivacaftor. 
